Abstract Over the last 40 years International Orthopaedics has published a series of articles on bone morphogenetic proteins (BMPs) covering topics from basic research to clinical applications. This includes also work submitted from the Laboratory for Mineralized Tissues of the School of Medicine University of Zagreb. Accordingly, we felt obliged to give a short summary of Dr. Urist's life and work as our gratitude to his discovery that demineralized bone matrix (DBM) activity induces bone when implanted ectopically into the muscle or under the skin due to bone inducing proteins, named BMPs.
muscle of animals [29] . With these studies, Dr. Urist pioneered the concept of substance naturally present in bone, responsible for the regeneration and bone repair activity. He called this substance the bone inductive principle BMP, bone morphogenetic protein, introducing the new term to describe the nature of this bone inductive factor and initiated a search for these molecules [30] . He spent the next three decades isolating and purifying BMP molecules. Throughout the 1970s, pre-clinical research in Dr. Urist's laboratory demonstrated the involvement of BMP in the bone formation cascade of mitosis, chemotaxis, differentiation, callus and bone formation (endochondral and intramembranous). The advances in molecular biology in the 1980s and early 1990s allowed the sequencing and cloning of BMPs. Cloned for the first time in 1988 by a research team at the Genetics Institute led by Dr. John Wozney, BMP proved to be a member of the TGF-beta superfamily of cytokines [40] . The first publications on the clinical use of BMP in non-unions and segmental bone defects began in the late 1980s by Johnson et al. [16] in tibial defects. Dr. Urist's work resulted in the publication of over 400 papers and the presentations of more than 200 lectures throughout the world. Availability of rhBMPs permitted the large scale evaluation of their efficacy and safety in a large number of animal models, thus allowing for optimization of both carrier and dose of BMPs for clinical use [6, 8-11, 13, 17, 19, 21, 22, 24, 27, 38] .
Native BMPs were tested in clinical trials under Dr. Urist's supervision at the University of California at Los Angeles (UCLA) where patients with difficult non-unions and bone defects were successfully treated.
We had an opportunity to personally interact ( Fig. 1 ) and exchange ideas regarding heterotopic ossification with Dr. Urist. The first contact was established in 1983 when Prof. Vukicevic contacted Dr. Urist regarding the discovery of heterotopic ossification in the anterior abdominal wall of a cadaver found during an anatomical dissection, a case report published in Plastic and Reconstructive Surgery [39] . The paper reported on a membranous bone transplant found in the anterior abdominal wall of an 82-year-old man. Histological and bone mineral content analyses revealed that bone graft underwent little bone resorption and induced new bone formation and that it represented a parietal skull bone removed following benign brain tumor surgery and implanted into the abdominal wall for a delayed skull closure [39] . Dr. Urist kindly replied to the letter, gave useful advice and shared some of his experience associated with heterotopic ossification. In the letter Dr. Urist mentioned that he was working with bone morphogenetic proteins (Fig. 2) , which in time became the main research interest of Professor Vukicevic and his scientific team as well as many international collaborators.
Dr. Vukicevic and Dr. Pecina explored the mechanisms and function of BMPs in patients with non-unions [3, 7, 20, 21, 26, [31] [32] [33] 37] , and Dr. Grgurevic made important contributions to understanding the role of circulating BMPs that led to the use of BMP6 locally in patients with bone defects [1, 26, [32] [33] [34] . With numerous collaborators they published important discoveries and organized international BMP conferences (Figs. 3 and 4) .
Dr. Urist was a distinguished leader and his contributions as a scientist, surgeon, clinician, writer and editor are legendary. He trained and mentored hundreds of young medical residents, fellows and researchers, and his bone laboratory became a centre of scientific and intellectual exchange. Dr. Urist won numerous academic honours, including two kappa Delta awards for his work on oestrogen effects on bone and work on BMPs. The First International Conference on BMP was also held at Johns Hopkins University in 1994 to honour Dr. Urist. In 1991, professor Ian Goldie nominated Dr. Urist for the Nobel Prize in Physiology or Medicine which was based on his early work on bone physiology and the discovery of bone formation, BMPs and his clinical research in orthopaedics.
The research area of BMPs has significantly expanded in the past two decades and covered many areas but has primarily remained in the field of bone regeneration. The foundation that Dr. Urist set by the discovery of BMPs provided a good basis for further preclinical research and development of new bone regeneration products by taking advantage of the basic characteristics of BMPs as a potent bone-forming agent in vivo, with the ability of restoring bone loss in postnatal life by recapitulation of events that are similar to those in the embryonic development. BMPs are members of the TGF beta superfamily and have diverse roles in development, repair and regeneration [34] [35] [36] [37] . BMP2 and BMP7 have been most studied in the context of bone healing [5, 9, 28] . Two therapeutic concepts have been introduced to the market to overcome bone non-healing or complicated bone fractures consisting of bovine collagen as a carrier which is soaked with BMP2 (Infuse Bone Graft) or BMP7 (Osigraft) [8, 18, 33] . BMP2 has received approval for several clinical indications (open tibial shaft fractures and anterior fusion of the lumbar spine in patients with degenerative disc disease [DDD] ). Due to serious side effects of BMP2 [12, 25] there is still a need to develop safer and more effective therapies for bone regeneration. In order to avoid the occurrence of side effects and limitations which include ectopic ossification outside the bone compartment, oedema, inflammation, bovine collagen as a BMP carrier, and a high product price, new therapeutic concepts are being developed and tested in a large number of preclinical animal models. OSTEOGROW is a new bone device consisting of BMP6 and a biocompatible blood coagulumderived carrier currently tested in Phase I/II clinical testing in patients with high tibial osteotomy (HTO) and distal radius fracture (DRF) in three European countries. The first safety report after completion of Phase II in patients with HTO indicate that no serious side effects have been reported [33, 34] .
The existence of a link between the founder and those who learn from him proved to be in accordance with the metaphor: standing on the shoulders of giants (Latin: nanos gigantum humeris insidentes) expressing the meaning of Bdiscovering truth by building on previous discoveries^. The concept has been traced to the 12th century, attributed to Bernard of Chartres [11] . The future of BMPs as regulators of almost all developmental and postnatal events provides a platform for future discoveries on segmental bone healing and systemic bone biology [34] . 
